ID
IDD.F Innate Pharma S.A
- Market cap
- EUR 155M
- P/E
- -
- P/B
- 31.00x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is IDD.F undervalued?
Graham numberThe Graham number of Innate Pharma S.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innate Pharma S.A fundamental analysis
No fundamental analysis for Innate Pharma S.A yet.
Innate Pharma S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innate Pharma S.A
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that…
Full company profileInnate Pharma S.A financial statements
Innate Pharma S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 56.2M | 32.6M | 79.9M | 69.0M | 56.8M | 12.1M | 49.6M | 51.9M | 12.6M | 2.79M |
| Gross Profit | 56.2M | 32.6M | 24.4M | 23.8M | 53.8M | - | - | - | - | - |
| Operating Income | 7.57M | -40.0M | 5.15M | -27.1M | -18.5M | -47.8M | -16.4M | -12.7M | -51.6M | -53.4M |
| EBITDA | - | -43.5M | 10.2M | -4.02M | -424K | -36.9M | -7.25M | -5.55M | -46.9M | -43.6M |
| Net Income | 12.6M | -48.4M | 3.05M | -20.8M | -64.0M | -52.8M | -58.1M | -7.57M | -49.5M | -49.2M |
| EPS | - | -0.84 | 0.05 | -0.26 | -0.81 | -0.66 | -0.73 | -0.09 | -0.59 | -0.52 |
| Balance Sheet | ||||||||||
| Total Assets | 282M | 255M | 451M | 401M | 307M | 267M | 208M | 184M | 111M | 62.7M |
| Total Liabilities | 195M | 169M | 284M | 184M | 151M | 160M | 154M | 132M | 102M | 84.4M |
| Shareholders' Equity | 86.2M | 86.0M | 167M | 217M | 156M | 107M | 54.2M | 51.9M | 8.83M | -21.7M |
| Cash & Short-term Investments | 176M | 99.4M | 152M | 203M | 137M | 104M | 84.2M | 70.6M | 66.4M | 28.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -36.9M | -48.1M | -32.5M | 34.9M | -51.8M | -58.5M | -19.2M | -52.8M | -6.90M | -32.6M |
| Capital Expenditure | 9.39M | 2.96M | 873K | 1.27M | 907K | 929K | 535K | 140K | 391K | 2.35M |
| Free Cash Flow | - | -54.1M | -34.0M | -30.5M | -63.1M | -59.8M | -20.3M | -52.9M | -7.29M | -34.9M |
| Ratios | ||||||||||
| ROE | 14.7% | -56.3% | 1.8% | -9.5% | -41.0% | -49.2% | -107.3% | -14.6% | -560.0% | - |
| ROA | 4.5% | -19.0% | 0.7% | -5.2% | -20.8% | -19.7% | -28.0% | -4.1% | -44.5% | -78.4% |
| Net Profit Margin | 22.5% | -148.3% | 3.8% | -30.1% | -112.6% | -436.0% | -117.1% | -14.6% | -392.0% | -1,764.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Innate Pharma S.A dividends
Innate Pharma S.A has not paid dividends in the last 10 fiscal years.
Who owns Innate Pharma S.A
- Insiders 17.46%
- Institutions 11.72%
- Public & others 70.82%
- Shares outstanding 112M
- Free float 68.9M
Innate Pharma S.A company profile
- Company name
- Innate Pharma S.A
- Ticker
- IDD.F
- ISIN
- FR0010331421
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 120
- Fiscal year end
- December
- Address
- 117, Avenue de Luminy, Marseille, France, 13009
- Phone
- 33 4 30 30 30 30
- Website
- innate-pharma.com
About Innate Pharma S.A
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Innate Pharma S.A management
10- Mr. Jonathan E. Dickinson B.Sc., M.B.A.CEO & Director · born 1968
- Mr. Yannis Morel Ph.D.Executive VP & COO · born 1973
- Dr. François Romagné Ph.D.Founder · born 1964
- Dr. Marc Bonneville Ph.D.Founder · born 1960
- Mr. Jean Jacques Fournié Ph.D.Founder
- Mr. Alessandro Moretta M.D., Ph.D.Founder
- Mr. Frederic Lombard M.B.A.Senior VP & CFO · born 1975
- Ms. Stephanie CornenVice President of Investor Relations, Communication & Commercial Strategy · born 1987
- Ms. Odile BelzunceVP, Chief of Compliance & Operations Officer and Interim Head of HR · born 1980
- Ms. Claire de Saint BlanquatVP of Legal & Corporate Affairs and Secretary of the Supervisory Board · born 1973